These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34902336)

  • 1. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
    Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
    Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis.
    Feng X; Goodley P; Alcala K; Guida F; Kaaks R; Vermeulen R; Downward GS; Bonet C; Colorado-Yohar SM; Albanes D; Weinstein SJ; Goldberg M; Zins M; Relton C; Langhammer A; Skogholt AH; Johansson M; Robbins HA
    Lancet Digit Health; 2024 Sep; 6(9):e614-e624. PubMed ID: 39179310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
    JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    J Thorac Oncol; 2020 Nov; 15(11):1738-1747. PubMed ID: 32822843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria-Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    JTO Clin Res Rep; 2021 Mar; 2(3):100137. PubMed ID: 34590000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
    Luo YH; Luo L; Wampfler JA; Wang Y; Liu D; Chen YM; Adjei AA; Midthun DE; Yang P
    Lancet Oncol; 2019 Aug; 20(8):1098-1108. PubMed ID: 31255490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
    JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.
    Ten Haaf K; Bastani M; Cao P; Jeon J; Toumazis I; Han SS; Plevritis SK; Blom EF; Kong CY; Tammemägi MC; Feuer EJ; Meza R; de Koning HJ
    J Natl Cancer Inst; 2020 May; 112(5):466-479. PubMed ID: 31566216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    Smeltzer MP; Liao W; Faris NR; Fehnel C; Goss J; Shepherd CJ; Ramos R; Qureshi T; Mukhopadhyay A; Ray MA; Osarogiagbon RU
    J Thorac Oncol; 2023 Feb; 18(2):158-168. PubMed ID: 36208717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.